Saturday 17 October 2026 Export BGMS’s income statement to Excel — free account

Bio Green Med Solution, Inc.

Bio Green Med Solution, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747,000.00, up 1,637.2% from fiscal 2024. In the quarter to June 2026, revenue grew 3,260.0%, EPS grew 91.8% and free cash flow grew 66.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.91 0.08 +9.64%

Follow BGMS

Alert me

Market cap: $5.5M
P/E: 0.0×
Fwd P/E: −0.3×
Dividend yield: 0.00%
F-score: 4/9
Altman Z: −78.86
Beneish M: n/a
Dividend safety: 20/100

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.05

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 13.37%

Capital & Financial Ratios $m

Market Cap 5.51

Revenue 1.86

Net Income (2.20)

Free Cash Flow (1.10)

Net Debt (3.79)

Current Ratio 8.63

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.34)

P/S ratio 2.74

P/B ratio 0.71

Past 5Y EPS Growth —

This Y EPS Growth 92.71%

Next Y EPS Growth 39.49%

Next Y revenue growth (86.61%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 3.79%

10-year low 10-year high

P/B against its own 10 years 42.84%

10-year low 10-year high

EV/Sales against its own 10 years 10.99%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 0.00

Annual Dividend Yield 0.00%

	total	individual payouts
2025	0.15	0.15
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack
2016	0.15	0.15

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	3	4	4
Receivables	—	—	1	1
Inventory	—	—	1	1
Other	—	—	—	—
	7	4	6	6

	2023	2024	2025	Q'26
Payables	4	5	1	0
ST’ Debt	—	—	—	—
Other	—	—	—	—
	8	6	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	(17.41%)	70.77%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(9.63%)	(27.11%)	(24.56%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	0	—	—	—
’25	—	—	0	1	1
’24	0	0	0	—	0
’23	—	0	0	0	0
’18	—	—	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	(3)	(1)	0	0	(5)
’24	0	(3)	(3)	(1)	(8)
’23	(7)	(1)	(4)	(4)	(16)
’22	(7)	(2)	(7)	(5)	(21)
’21	(4)	(4)	(6)	(5)	(19)
’20	(3)	(2)	(2)	(1)	(8)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	(3)	(1)	0	0	(5)
’24	0	(3)	(3)	(1)	(8)
’23	(7)	(1)	(4)	(4)	(16)
’22	(7)	(2)	(7)	(5)	(21)
’21	(4)	(4)	(6)	(5)	(19)
’20	(3)	(2)	(2)	(1)	(8)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.04)	(0.08)	—	—	—
’25	(0.22)	(0.98)	(1.31)	(2.21)	(6.45)
’24	(34.03)	(172.71)	(43.18)	(79.16)	(501.35)
’23	(1.69k)	(1.58k)	(114.20)	(1.49k)	(6.42k)
’22	(1.51k)	(1.65k)	(1.51k)	(2.16k)	(6.83k)
’21	(1.80k)	(2.01k)	(1.94k)	(1.94k)	(7.70k)
’20	(5.32k)	(2.09k)	(1.69k)	(4.82k)	(13.92k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	219,600.00	108,000.00	36,720.00	20,160.00	11,232.00	11,340.00	1,908.00	528.00	74.40	1.16	Analyst estimates 2026–2028 Powerpack
	High	699,840.00	784,800.00	138,960.00	84,960.00	70,560.00	41,112.00	16,308.00	4,212.00	960.00	213.60
People
People	Employees	13	12	14	12	12	12	12	8	6	19
	Revenue/emp, $m	0.06	0.00	0.01	0.00	0.00	0.00	0.00	0.05	0.01	0.04
Income, $m
Income, $m	Revenue	1	—	0	—	—	—	—	0	0	1
	Gross margin, %	100.00	0.00	100.00	0.00	0.00	0.00	0.00	100.00	100.00	18.47
	EBT	(14)	(8)	(9)	(9)	(10)	(22)	(26)	(26)	(12)	(3)
	EBT margin, %	(1,633.93)	0.00	(5,750.00)	0.00	0.00	0.00	0.00	(6,083.57)	(27,893.02)	(400.40)
	Net income	(12)	(7)	(7)	(8)	(8)	(18)	(21)	(23)	(11)	(3)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	750.00	0.00	0.00	0.00	0.00	120.00	1.93	0.34
	Earnings	(251,748.20)	(67,130.68)	(44,595.39)	(39,560.43)	(13,918.08)	(7,696.30)	(6,833.17)	(6,416.79)	(501.35)	(6.45)
	Cash flow	0.00	(74,800.00)	(33,505.00)	(47,235.00)	(7,934.00)	(7,416.00)	(7,713.70)	(4,603.43)	(358.30)	(2.18)
	Capex	0.00	(130.00)	(195.00)	140.00	(96.00)	(10.80)	(2.59)	(1.71)	0.00	0.00
	Free cash flow	0.00	(74,930.00)	(33,700.00)	(47,095.00)	(8,030.00)	(7,426.80)	(7,716.30)	(4,605.14)	(358.30)	(2.18)
	Book value	0.00	217,660.00	76,360.00	58,485.00	33,259.00	15,077.20	5,903.33	173.43	(97.49)	3.13
	Shares, m	0	0	0	0	0	0	0	0	0	2
Valuation, ×
Valuation, ×	P/E	0.00	—	0.00	—	—	—	—	0.00	0.00	0.00
	P/S	0.00	—	10.42	—	—	—	—	3.19	27.48	4.25
	P/B	0.00	—	0.58	—	—	—	—	3.67	0.00	0.47
	EV/Sales	(19.60)	—	(10.34)	—	—	—	—	(1.65)	(14.91)	(0.36)
	EV/FCF	1.65	—	1.31	—	—	—	—	0.07	0.14	0.06
Cash, $m
Cash, $m	Operating cash flow	(10)	(7)	(7)	(9)	(8)	(19)	(21)	(16)	(8)	(5)
	Capex	0	0	0	0	0	0	0	0	—	—
	Free cash flow	(10)	(7)	(7)	(9)	(8)	(19)	(21)	(16)	(8)	(5)
Balance, $m
Balance, $m	Working capital	14	22	15	12	33	36	17	(1)	(3)	5
	Total debt	—	—	—	1	1	0	0	—	—	—
	Net debt	(17)	(24)	(18)	(12)	(33)	(37)	(18)	(3)	(3)	(4)
	Shareholders’ equity	14	22	15	12	33	38	16	1	(2)	7
Returns, %
Returns, %	ROA	(53.98)	(65.02)	(32.68)	(45.72)	(47.67)	(46.68)	(60.12)	(123.49)	(173.84)	(229.53)
	ROIC	0.00	0.00	0.00	0.00	0.00	(1,233.96)	0.00	0.00	0.00	(157.83)
	ROE	(72.44)	(82.39)	(40.44)	(59.56)	(55.26)	(52.59)	(79.80)	(275.06)	1,431.01	(603.77)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NRSN NeuroSense Therapeutics Ltd.	$6.0M	— (loss-making)	—	—	n/m	−23,458.82% (below 0%: shrinking)	—	0.00%	Compare
IMNN Imunon, Inc.	$6.0M	— (loss-making)	— (loss-making)	0.00%	n/m	−4.24% (below 0%: shrinking)	0.00%	0.00%	Compare
ORGS Orgenesis Inc.	$5.7M	— (loss-making)	1.0×	+82.42% (above 0%: growing)	n/m	−317.93% (below 0%: shrinking)	2,780.73%	(6,044.52%)	Compare
CANF Can-Fite Biopharma Ltd	$5.6M	— (loss-making)	— (loss-making)	−1.18% (below 0%: shrinking)	n/m	+12.63% (above 0%: growing)	0.00%	0.00%	Compare
BGMS Bio Green Med Solution, Inc.	$5.5M	— (loss-making)	— (loss-making)	+3,260.00% (above 0%: growing)	n/m	+66.67% (above 0%: growing)	23.51%	(124.40%)
CELZ Creative Medical Technology Holdings, Inc.	$5.4M	— (loss-making)	— (loss-making)	0.00%	n/m	−27.05% (below 0%: shrinking)	66.67%	0.00%	Compare
CDIO Cardio Diagnostics Holdings, Inc.	$5.2M	— (loss-making)	— (loss-making)	−28.00% (below 0%: shrinking)	n/m	+15.58% (above 0%: growing)	100.00%	(27,742.59%)	Compare
PULM Pulmatrix, Inc.	$5.2M	— (loss-making)	— (loss-making)	−99.86% (below 0%: shrinking)	n/m	+41.26% (above 0%: growing)	100.00%	0.00%	Compare
RVPH Reviva Pharmaceuticals Holdings, Inc.	$5.0M	— (loss-making)	—	—	n/m	+57.80% (above 0%: growing)	—	0.00%	Compare
Median of peers	$5.5M	—	—	−0.59%	—	+4.20%	83.34%	0.00%

All 614 Biotechnology stocks →

Bio Green Med Solution, Inc. (BGMS) key facts

Strength: Bio Green Med Solution, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747,000.00, up 1,637.2% from fiscal 2024.
Bio Green Med Solution, Inc. (BGMS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, BGMS traded at $0.91, a market capitalization of $5.5 million.
Return on equity was −603.8% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −78.86 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.